 CRANFORD, N.J., March 3, 2022 PRNewswire -- Citius Pharmaceuticals, Inc. Citius or the Company Nasdaq: CTXR, a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will be presenting at two investor conferences in March 2022. 